Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricGMABGenmab A/SABVXAbivax SAINCYIncyte
Snapshot
Price$28.40$133.90$117.71
Market cap$16.18B$11.63B$23.35B
Valuation
P/E20.9x—16.5x
Forward P/E27.9x—11.8x
Growth
Revenue growth20.7%—21.5%
EPS growth-25.3%—2455.3%
Profitability
Net margin21.1%—26.7%
ROE14.5%-51.7%29.2%
Balance sheet & cash
Debt / equity0.93x0x0.01x
Free cash flow yield—-2.1%2.2%
Dividend yield———
Verdict
Investment ratingFavorable· 62Weak· 35Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearGMABtoday $28ABVXtoday $134INCYtoday $118
2027$21.73 – $31.86+12% CAGR$107.45 – $157.60+18% CAGR$2,255.89 – $3,308.64+2711% CAGR
2028$22.16 – $32.50+7% CAGR$114.98 – $168.63+12% CAGR$57,645.02 – $84,546.03+2580% CAGR
2029$22.60 – $33.15+5% CAGR$123.02 – $180.44+10% CAGR$1,473,009.02 – $2,160,413.23+2538% CAGR
2030$23.06 – $33.82+4% CAGR$131.64 – $193.07+10% CAGR$37,639,946.83 – $55,205,255.35+2517% CAGR
2031$23.52 – $34.49+4% CAGR$140.85 – $206.58+9% CAGR$961,817,325.28 – $1,410,665,410.42+2504% CAGR
5-yr CAGR-3.7% – 4.0%1.0% – 9.1%2312.4% – 2504.5%